A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Auto-Injector and the Etanercept Prefilled Syringe) in Patients With Psoriasis.

Trial Profile

A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Auto-Injector and the Etanercept Prefilled Syringe) in Patients With Psoriasis.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2012

At a glance

  • Drugs Etanercept (Primary)
  • Indications Psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Wyeth Pharmaceuticals
  • Most Recent Events

    • 01 Apr 2012 Results published in the Journal of the European Academy of Dermatology and Venereology.
    • 29 Mar 2012 Actual patient number is 421 according to ClinicalTrials.gov.
    • 09 Jun 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top